Advancing global antibiotic research, development and access.

Area of Science:

• * Infectious Diseases
• * Pharmaceutical R&D
• * Public Health Policy

Background:

• * The global burden of drug-resistant infections is increasing, outpacing the development of new antibiotics.
• * Economic challenges and declining private investment hinder antibiotic research and development (R&D).
• * Antibiotic shortages and inequitable access to treatments are critical issues worldwide.

Purpose of the Study:

• * To highlight the critical need for increased investment and commitment to antibiotic R&D.
• * To emphasize the growing role of public and philanthropic funding in addressing antibiotic resistance.
• * To advocate for policies ensuring equitable access to existing and novel antibiotic treatments.

Main Methods:

• * Analysis of the current state of antibiotic R&D investment and challenges.
• * Review of emerging public-private partnerships and funding models (e.g., CARB-X, GARDP, AMR Action Fund).
• * Examination of innovative reimbursement and evaluation schemes for antibiotics.

Main Results:

• * A significant gap exists between the need for new antibiotics and the current R&D pipeline.
• * Public and philanthropic initiatives are increasingly vital in supporting antibiotic R&D.
• * Innovative funding and access strategies are being piloted to address market failures.

Conclusions:

• * Urgent global leadership and commitment are required to bolster the antibiotic R&D ecosystem.
• * Incentivizing public health-driven R&D across all sectors is essential.
• * Ensuring universal access to effective antibiotics must be a global priority.